Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Biotech Partners to Focus on Drugs Targeting G-Protein Coupled Receptors

By BiotechDaily International staff writers
Posted on 05 Nov 2012
An agreement between the French company Domain Therapeutics (Illkirch-Strasbourg, France) and Japanese Ono Pharmaceutical Co., Ltd. (Osaka, Japan) is designed to promote the discovery of small molecules targeting G-Protein Coupled Receptors (GPCRs).

GPCRs are not only the largest protein family in the human genome but also the single biggest target for therapeutic agents. Ligand binding to these receptors activates their associated G protein, which then activates an effector enzyme to generate an intracellular second messenger. All GPCRs contain seven membrane-spanning regions with their N-terminal segment on the external face and their C-terminal segment on the cytosolic face of the plasma membrane. This large receptor family includes light-activated receptors (rhodopsins) in the eye and thousands of odorant receptors in the nose, as well as numerous receptors for various hormones and neurotransmitters. Although these receptors are activated by different ligands and may mediate different cellular responses, they all mediate a similar signaling pathway.

Under the terms of the collaborative agreement for development of GPRC-directed drugs, Ono Pharmaceutical will provide Domain Therapeutics with an upfront payment and provide research funding for collaborative research programs and success-based milestones. Domain Therapeutics will receive royalties on sales of the products.

Domain Therapeutics will apply its proprietary DTect-All GPCR drug discovery platform and utilize its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono Pharmaceutical.

Ono Pharmaceutical will then have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.

“This collaboration with Ono further confirms the value of our differentiated drug discovery process and of our expertise in the field of GPCRs. It constitutes an important step towards the objective of Domain Therapeutics to collaborate with pharma partners on integrated projects, from target to drug candidate,” said Pascal Neuville, CEO of Domain Therapeutics. “We are delighted to be collaborating with Ono, which is recognized as a leading Japanese pharmaceutical company.”

Dr. Kazuhito Kawabata, executive director of discovery and research at Ono Pharmaceutical, said, “We highly appreciate Domain Therapeutics’ DTect-All technology and strongly believe that the company is the partner of choice to identify GPCR drugs. This collaboration will strengthen Ono’s drug discovery capability in research areas of Ono’s expertise with significant unmet medical needs. We are expecting that innovative drugs will be created through this collaboration.”

Related Links:

Ono Pharmaceutical
Domain Therapeutics


Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.